Extended: GLP-1 Metabolism & Cardiovascular Panel (Quest)

What this panel includes

• Lipid panel with ratios: Assesses cholesterol balance and cardiovascular risk trends

• Apolipoprotein B: Evaluates atherogenic particle burden

• Lipoprotein(a): A genetically influenced cardiovascular risk marker that impacts risk irrespective of cholesterol levels

• High sensitivity C reactive protein (hs CRP): Tracks systemic inflammation, which is a significant risk factor for all diseases

• Uric acid: Provides insight into metabolic stress and inflammation

• Comprehensive metabolic panel (CMP): Includes fasting glucose and markers of liver, kidney, and electrolyte balance

• Fasting insulin and hemoglobin A1c: Assess insulin sensitivity and longer term blood sugar control

• Leptin: Evaluates energy balance signaling and metabolic adaptation

• CBC with differential: Offers context on overall health and inflammatory or physiologic stress

• Thyroid function: TSH, free T4, and free T3 to assess metabolic regulation

• Vitamin B12: Essential for neurologic function, energy production, and red blood cell formation

Biomarkers tested

Why patients choose this

• A structured way to monitor blood sugar, lipids, and inflammation while on GLP-1 therapy, offering objective insight into how the body is responding.
• Tracks trends in blood sugar regulation, lipid balance, and systemic inflammation over the course of treatment.
• Designed to complement GLP-1 therapy, including Tirzepatide and Semaglutide.
• Recommended every three to six months for individuals actively using GLP-1 medications.
• Schedule your lab test seamlessly and complete it at a lab near you.

Before your test

It is recommended to fast for at least 8 hours before.

Important information

Why it matters: GLP-1 therapies influence appetite regulation, insulin sensitivity, inflammation, and cardiometabolic markers over time, and tracking these pathways supports informed, personalized care and long-term metabolic health.

Who it's for: recommended every three to six months for individuals actively using GLP-1 medications.

While lab values provide valuable context, they are not used in isolation to determine treatment decisions. Symptoms, body composition, and overall clinical response remain the primary drivers of therapy adjustments.

It is recommended to fast for at least 8 hours before your draw.